A summary of current research into CD4 cell loss in early infection and its implications for HIV prevention, by NAPWA policy analyst Kirsty Machon. Post-Exposure Prophylaxis
11 October 2005 - 10:58am
A summary of current research into CD4 cell loss in early infection and its implications for HIV prevention, by NAPWA policy analyst Kirsty Machon. 1 July 2002 - 12:00am
1 July 2001 - 12:00am
In Australia, at the time of writing, PEP is available for non-occupational exposures to HIV (such as through sex or injecting drug use) only in NSW, Queensland and the ACT, and through one hospital in Victoria. In many other countries it is not available at all, or you have to pay the full cost of the treatment. PEP is a course of anti-HIV drugs taken at specific times of the day for a period of four weeks. PEP does not guarantee prevention of HIV infection. However, research shows that PEP may significantly decrease the chances of infection after exposure to HIV.